Cholecalciferol
Other / unclassified targets NGF, PRODH, VDR via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Fosavance | — | 2005-08-24 | europa.eu ↗ |
| Approved | US (FDA) | INFUVITE ADULT | — | 2000-05-18 | fda.gov ↗ |
Trials 357 · started per year
Also used as a comparator or background therapy in 208 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06073925 Comparator | Dec 2023 → Jul 2024 | autoimmune thrombocytopenia | Mansoura University | Unknown | No outcome recorded |
| Phase 0 | NCT02337257 Comparator | Apr 2014 → Sep 2015 | periodontitis, vitamin D deficiency | Augusta University | Unknown | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT06515548 Comparator | Aug 2024 → Feb 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT06565728 Comparator | Nov 2022 → May 2023 | fetal growth restriction | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT05739786 Comparator | May → Nov 2022 | common wart | Combined Military Hospital Abbottabad | Completed | No outcome recorded |
| Phase 1 | NCT02698293 Background | Dec 2019 → Jan 2023 | anus disorder, in situ carcinoma | Abramson Cancer Center at Penn Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT03475719 Comparator | Jan → Feb 2018 | postmenopausal osteoporosis | Huons Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03382314 Comparator | Oct → Dec 2017 | osteoporosis | Hyundai Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Phase 1 | NCT03234244 Comparator | Apr → Aug 2017 | osteoporosis | Hyundai Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Phase 1 | NCT03781895 Comparator | Mar 2017 → Feb 2018 | chronic obstructive pulmonary disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 1 | NCT02185196 Comparator | Jun 2014 → Dec 2017 | pneumonia | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 1 | NCT01909115 Comparator | Sep 2013 → Sep 2014 | chronic kidney disease | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02273843 Comparator | Sep 2013 → Aug 2015 | neonatal sepsis | Mansoura University Children Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01577849 Comparator | Mar → Jun 2012 | — | Alvogen Korea | Completed | No outcome recorded |
| Phase 1 | NCT01024777 Comparator | Mar 2010 → Jan 2013 | multiple sclerosis, vitamin D deficiency | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01046773 Comparator | Jan 2010 → May 2017 | Crohn disease, vitamin D deficiency | University of California, Los Angeles | Terminated | No outcome recorded |
| Phase 1 | NCT00682214 Comparator | May → Nov 2008 | vitamin D deficiency | Indian Council of Medical Research | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06301178 Comparator | Feb 2024 → Feb 2025 | skin disorder | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 1/2 | NCT04489628 Comparator | Aug 2020 → Jun 2021 | COVID-19 | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04591600 Background | Jul → Sep 2020 | COVID-19 | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| Phase 1/2 | NCT03406897 Comparator | Jul 2018 → Jul 2024 | hypoglycemia, type 1 diabetes mellitus | Rodolfo Alejandro | Completed | No outcome recorded |
| Phase 1/2 | NCT03101150 Comparator | Oct 2012 → Oct 2014 | preeclampsia, vitamin D deficiency | King Fahad Medical City | Completed | No outcome recorded |
| Phase 1/2 | NCT01170507 Comparator | Dec 2011 → Aug 2016 | vitamin D deficiency | King Faisal Specialist Hospital & Research Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01131858 Comparator | Mar 2010 → Jun 2011 | inborn error of immunity | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 238 trials | ||||||
| Phase 2 | NCT06596122 Comparator | Oct 2024 → Nov 2026 expected | neuropathy, painful | Abdelrahman Mahmoud | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05578404 Comparator | Oct 2022 → Apr 2023 | NAFLD1 | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05104970 Comparator | Aug 2022 → Jan 2023 | vitamin D deficiency | Scotmann Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT04067726 Background | Aug 2019 → Sep 2025 overdue | female breast upper-inner quadrant cancer | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04011930 Comparator | Mar 2019 → Feb 2020 | chronic obstructive pulmonary disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2 | NCT03405207 Comparator | May → Oct 2018 | myocardial infarction, vitamin D deficiency | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03426592 Comparator | Jan 2018 → May 2019 | HIV infectious disease | University of Melbourne | Completed | No outcome recorded |
| Phase 2 | NCT02854722 Background | Jan 2018 → Jun 2019 | postmenopausal osteoporosis | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT03038516 Comparator | Nov 2017 → Jun 2020 | vitamin D deficiency | Region Stockholm | Completed | No outcome recorded |
| Phase 2 | NCT01968590 Comparator | Aug 2017 → Jan 2022 | neurofibromatosis type 1 | University of Utah | Terminated | No outcome recorded |
| Phase 2 | NCT03799406 Comparator | Oct 2016 → Mar 2017 | acute bronchiolitis | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT01728987 Comparator | Aug 2016 → Dec 2018 | obesity disorder | University of Tromso | Withdrawn | No outcome recorded |
| Phase 2 | NCT02537509 Comparator | Oct 2015 → Mar 2023 | atopic eczema | Rennes University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02416193 Comparator | Sep 2015 → Jul 2018 | type 2 diabetes mellitus | Loyola University | Terminated | No outcome recorded |
| Phase 2 | NCT02550912 Comparator | Aug 2015 → Feb 2016 | autism | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02387164 Background | Mar 2015 → Oct 2019 | prediabetes syndrome, type 1 diabetes mellitus | Lund University | Terminated | No outcome recorded |
| Phase 2 | NCT02074631 Background | Feb 2015 → Oct 2022 | osteoporosis | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02178488 Comparator | Dec 2014 → Dec 2017 | methicillin-resistant staphylococcus aureus infectious disease, vitamin D deficiency | Peter Bergman | Completed | No outcome recorded |
| Phase 2 | NCT02783924 Comparator | Oct 2014 → Sep 2017 | vitamin D deficiency | University of Tromso | Completed | No outcome recorded |
| Phase 2 | NCT02224144 Background | Aug 2014 → Oct 2016 | bone resorption disease, calcinosis, end stage renal failure | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT02192229 Comparator | Aug → Nov 2014 | vitamin D deficiency | Hayat Pharmaceutical Co. PLC | Unknown | No outcome recorded |
| Phase 2 | NCT01702974 Comparator | Sep 2012 → Aug 2015 | HIV infectious disease | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT01698476 Comparator | Sep 2012 → Aug 2015 | pulmonary tuberculosis | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT01636570 Comparator | Aug 2012 → Apr 2015 | cardiomyopathy, congestive heart failure, vitamin D deficiency | Heidi Moretti, MS, RD | Completed | No outcome recorded |
| Phase 2 | NCT01974245 Comparator | Jul 2012 → Jul 2014 | chronic kidney disease | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT01532349 Comparator | May 2012 → Apr 2015 | anemia due to chronic disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01509079 Comparator | Mar 2012 → Oct 2014 | arthropathy, myofascial pain syndrome | HealthPartners Institute | Completed | No outcome recorded |
| Phase 2 | NCT02726113 Comparator | Oct 2011 → Mar 2015 | prostate cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT01419730 Comparator | Aug 2011 → Dec 2024 overdue | osteoporosis | University of Rochester | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01119131 Comparator | May 2011 → Jan 2015 | Parkinson disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01312714 Comparator | Feb 2011 → Sep 2012 | end stage renal failure | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 2 | NCT01580007 Comparator | Dec 2010 → Dec 2014 | pulmonary tuberculosis | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 2 | NCT01166165 Comparator | Jul 2010 → Apr 2011 | hypertensive disorder, vitamin D deficiency | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 2 | NCT01092338 Comparator | Jan 2010 → Jan 2011 | AIDS | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 2 | NCT00996801 Background | Nov 2009 → Jun 2011 | postmenopausal osteoporosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00859651 Comparator | Jun 2009 → Apr 2015 | breast cancer | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT00812578 Comparator | Dec 2008 → Jun 2010 | type 2 diabetes mellitus, vitamin D deficiency | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT00004488 Background | Oct 1998 → Sep 2002 | Gaucher disease, osteoporosis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT05922696 Comparator | May → Sep 2022 | anemia, vitamin D deficiency | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT05460338 Comparator | May → Sep 2022 | vitamin D deficiency | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT04145492 Comparator | Sep 2019 → Jan 2020 | end stage renal failure | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03911843 Background | Jan 2017 → Dec 2018 | type 1 diabetes mellitus | Azienda Ospedaliero Universitaria Maggiore della Carita | Completed | No outcome recorded |
| Phase 2/3 | NCT02738619 Comparator | Mar → Dec 2016 | allergic disease | Hospital General de Mexico | Unknown | No outcome recorded |
| Phase 2/3 | NCT01736865 Comparator | Dec 2012 → Aug 2015 | type 2 diabetes mellitus | Tufts Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT01708005 Comparator | Nov 2012 → Nov 2014 | cognitive impairment with or without cerebellar ataxia | University Hospital, Angers | Unknown | No outcome recorded |
| Phase 2/3 | NCT01304927 Comparator | Feb 2011 → Dec 2014 | male infertility | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2/3 | NCT01005303 Comparator | Feb 2009 → Aug 2013 | heart failure | Belfast Health and Social Care Trust | Completed | No outcome recorded |
| Phase 2/3 | NCT01432704 Comparator | Mar 2008 → May 2011 | multiple sclerosis | University of Turku | Completed | No outcome recorded |
| Phase 339 trials | ||||||
| Phase 3 | NCT07448974 Comparator | May 2026 → Mar 2030 expected | prediabetes syndrome, type 2 diabetes mellitus | Tufts Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07229456 Comparator | Oct 2024 → Oct 2025 overdue | — | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06690723 Comparator | Jun 2022 → Sep 2024 | obstructive sleep apnea syndrome | University Malaysia Sarawak | Completed | No outcome recorded |
| Phase 3 | NCT05305183 Background | May 2022 → May 2023 | osteoporosis | Shandong New Time Pharmaceutical Co., LTD | Unknown | No outcome recorded |
| Phase 3 | NCT04883203 Comparator | Apr → Sep 2020 | COVID-19 | University of Monastir | Completed | No outcome recorded |
| Phase 3 | NCT03284294 Comparator | Apr → Aug 2020 | schizophrenia | Padjadjaran University | Unknown | No outcome recorded |
| Phase 3 | NCT03920150 Comparator | Sep 2019 → May 2020 | vitamin D deficiency | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 3 | NCT04476511 Comparator | Sep 2018 → Dec 2021 | vitamin D deficiency | Semmelweis University | Completed | No outcome recorded |
| Phase 3 | NCT03536845 Comparator | Jan 2018 → Aug 2021 | epilepsy, vitamin D deficiency | King Saud University | Completed | No outcome recorded |
| Phase 3 | NCT02684487 Comparator | Dec 2017 → Jul 2022 | infectious disease with sepsis, multiple organ dysfunction syndrome | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT03096314 Comparator | Apr 2017 → Dec 2018 | acute respiratory distress syndrome, vitamin D deficiency | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02571660 Comparator | Nov 2015 → Nov 2016 | asthma | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Unknown | No outcome recorded |
| Phase 3 | NCT02594579 Comparator | Oct 2015 → Dec 2016 | muscular atrophy, vitamin D deficiency | Mahidol University | Unknown | No outcome recorded |
| Phase 3 | NCT02419105 Comparator | Sep 2015 → May 2020 | hypogonadism | University of Zurich | Terminated | No outcome recorded |
| Phase 3 | NCT02750293 Comparator | Jun 2015 → Aug 2017 | vitamin D deficiency | University of Tromso | Completed | No outcome recorded |
| Phase 3 | NCT03142620 Comparator | Mar 2015 → Dec 2017 | Helicobacter pylori infectious disease | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT02186600 Background | Feb 2015 → Jun 2019 | — | University of Nebraska | Completed | No outcome recorded |
| Phase 3 | NCT02734446 Comparator | Apr 2014 → Feb 2015 | asthma | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 3 | NCT02328404 Comparator | Feb → Sep 2014 | polycystic ovary syndrome, vitamin D deficiency | Hayat Pharmaceutical Co. PLC | Completed | No outcome recorded |
| Phase 3 | NCT02053519 Comparator | Feb 2014 → Apr 2016 | hepatitis C virus infection | University of Dundee | Completed | No outcome recorded |
| Phase 3 | NCT01932788 Comparator | Jan 2013 → Apr 2017 | vitamin D deficiency | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 3 | NCT01689779 Comparator | Jan 2013 → May 2015 | vitamin D deficiency | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01745263 Comparator | Dec 2012 → Nov 2017 | — | University of Zurich | Completed | No outcome recorded |
| Phase 3 | NCT01695460 Comparator | Sep 2012 → Dec 2015 | migraine disorder | Aalborg University | Completed | No outcome recorded |
| Phase 3 | NCT01490502 Comparator | Mar 2012 → May 2021 | relapsing-remitting multiple sclerosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT01518959 Comparator | Jan 2012 → Jan 2017 | B-cell chronic lymphocytic leukemia | Semmelweis University | Terminated | No outcome recorded |
| Phase 3 | NCT01419262 Comparator | Sep 2011 → May 2015 | asthma, respiratory tract infectious disorder, vitamin deficiency disorder | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT01409694 Comparator | Sep 2011 → Jan 2016 | Alzheimer disease | University Hospital, Angers | Completed | No outcome recorded |
| Phase 3 | NCT01190683 Comparator | Aug 2010 → Apr 2011 | vitamin D deficiency | Indian Council of Medical Research | Completed | No outcome recorded |
| Phase 3 | NCT01173848 Comparator | Jul 2010 → Sep 2011 | chronic kidney disease | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 3 | NCT01138475 Comparator | Jul 2010 → Aug 2015 | secondary hyperparathyroidism | Kerstyn C. Zalesin, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT00968877 Comparator | Sep → Dec 2009 | chronic kidney disease, vitamin D deficiency | Odense University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00752401 Comparator | May 2009 → Jul 2014 | renal osteodystrophy, vitamin D deficiency | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 3 | NCT00729183 Background | Oct 2008 → Mar 2010 | osteoporosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00677339 Comparator | Jun 2008 → Feb 2010 | pulmonary tuberculosis | Menzies School of Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00507000 Comparator | May 2008 → Sep 2010 | tuberculosis | Indian Council of Medical Research | Unknown | No outcome recorded |
| Phase 3 | NCT01608451 Comparator | Sep 2007 → Aug 2021 | female breast carcinoma | Tata Memorial Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00412074 Comparator | Aug 2006 → Oct 2012 | vitamin D deficiency | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 3 | NCT00504946 Comparator | Sep 2005 → Mar 2007 | asthma | Medical University of Lodz | Completed | No outcome recorded |
| Phase 455 trials | ||||||
| Phase 4 | NCT07510568 Comparator | Jun 2026 → Dec 2027 expected | HELLP syndrome, eclampsia | St Mary's Hospital, Lacor | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07448844 Comparator | Feb → May 2026 overdue | common wart, plantar wart | Riphah International University | Recruiting | No outcome recorded |
| Phase 4 | NCT07196670 Comparator | Sep → Dec 2025 overdue | plantar wart | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06551337 Comparator | Apr 2024 → Dec 2026 expected | bronchiectasis | Queen Mary Hospital, Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT05884372 Comparator | Aug 2023 → Jul 2025 | postmenopausal osteoporosis | Xi'an Honghui Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05860270 Comparator | Jun 2023 → Mar 2026 overdue | peritonitis, vitamin D deficiency | Peking University First Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06508242 Comparator | Apr 2023 → Dec 2024 | musculoskeletal system disorder, overnutrition | Fondazione Policlinico Universitario Campus Bio-Medico | Unknown | No outcome recorded |
| Phase 4 | NCT05733117 Comparator | Oct 2022 → Apr 2023 | vitamin D deficiency | Tomas Bata Hospital, Czech Republic | Unknown | No outcome recorded |
| Phase 4 | NCT03063190 Comparator | Mar 2022 | end stage renal failure, renal osteodystrophy, restless legs syndrome, vitamin D deficiency | University of Sao Paulo General Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT05244018 Comparator | Mar → Oct 2022 | infectious disease with sepsis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05002530 Background | Nov → Dec 2021 | anosmia | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 4 | NCT02393482 Comparator | Jun → Dec 2021 | amenorrhea, endometriosis | University of Cagliari | Unknown | No outcome recorded |
| Phase 4 | NCT05386784 Comparator | Dec 2020 → Jul 2022 | osteoporosis | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT04552951 Comparator | Apr → Sep 2020 | COVID-19 | Fundación para la Investigación Biosanitaria del Principado de Asturias | Unknown | No outcome recorded |
| Phase 4 | NCT05166005 Comparator | Apr 2020 → Aug 2021 | COVID-19 | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Unknown | No outcome recorded |
| Phase 4 | NCT04118010 Comparator | Mar 2020 → Dec 2022 | cystic fibrosis | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT05431218 Comparator | Feb 2020 → Dec 2021 | chronic obstructive pulmonary disease | Karaganda Medical University | Completed | No outcome recorded |
| Phase 4 | NCT04151823 Background | Jan 2019 → Jan 2021 | — | University of Milan | Unknown | No outcome recorded |
| Phase 4 | NCT04618952 Comparator | Jan 2019 → Aug 2020 | hypertensive disorder | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT04010942 Comparator | Apr → Dec 2018 | polycystic ovary syndrome, vitamin D deficiency | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04377399 Comparator | Jan 2018 → Jun 2019 | diabetic neuropathy, type 2 diabetes mellitus, vitamin D deficiency | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Completed | No outcome recorded |
| Phase 4 | NCT03257215 Comparator | Oct 2017 → Jan 2025 | atopic eczema | Murdoch Childrens Research Institute | Terminated | No outcome recorded |
| Phase 4 | NCT03141593 Comparator | Oct 2017 → Oct 2018 | vitamin D deficiency | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT03369379 Comparator | May → Dec 2017 | fibromyalgia, vitamin D deficiency | Autonomous University of Nuevo León | Completed | No outcome recorded |
| Phase 4 | NCT03006003 Comparator | Jan 2017 → Dec 2021 | depressive disorder | Taichung Veterans General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03005496 Comparator | Jan → Apr 2017 | — | Indonesia University | Completed | No outcome recorded |
| Phase 4 | NCT02958501 Comparator | Nov 2016 → Apr 2017 | nutritional disorder | Faculty Hospital Kralovske Vinohrady | Unknown | No outcome recorded |
| Phase 4 | NCT02507843 Comparator | Jan 2015 → Dec 2016 | bronchiectasis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 4 | NCT02617771 Comparator | Oct 2014 → Mar 2015 | respiratory tract infectious disorder | Policlinico Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02234544 Comparator | Oct 2014 → Apr 2015 | vitamin D deficiency | Federal University of Rio Grande do Sul | Completed | No outcome recorded |
| Phase 4 | NCT02389179 Comparator | Aug 2014 → Jul 2016 | vitamin D deficiency | Sharifah Faradila bt Wan Muhamad Hatta | Unknown | No outcome recorded |
| Phase 4 | NCT02092376 Comparator | Mar 2014 → Oct 2015 | — | Maria Luger | Completed | No outcome recorded |
| Phase 4 | NCT02031692 Comparator | Dec 2013 → May 2017 | benign paroxysmal positional vertigo | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02460380 Comparator | Oct 2013 → Mar 2015 | polycystic ovary syndrome, vitamin D deficiency | Maimonides Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01845142 Comparator | Feb → May 2013 | vitamin D deficiency | Margitta Worm | Completed | No outcome recorded |
| Phase 4 | NCT01765010 Comparator | Jan → Mar 2013 | osteoporosis | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01601847 Comparator | Jan 2013 → Mar 2017 | allergic disease, asthma | Case Western Reserve University | Completed | No outcome recorded |
| Phase 4 | NCT01741181 Comparator | Sep 2012 → Nov 2014 | type 2 diabetes mellitus, vitamin D deficiency | Tan Tock Seng Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04609189 Comparator | Jul 2012 → May 2014 | postmenopausal osteoporosis | University of Alberta | Completed | No outcome recorded |
| Phase 4 | NCT03644212 Comparator | Jul 2012 → Sep 2013 | polycystic ovary syndrome, vitamin D deficiency | Maimonides Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01632514 Comparator | Jun 2012 → Jun 2017 | — | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01588795 Comparator | Apr 2012 → Jan 2016 | diabetic kidney disease, proteinuria | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT01559974 Comparator | Nov 2011 → Jan 2013 | peripheral arterial disease | University Hospital, Basel, Switzerland | Terminated | No outcome recorded |
| Phase 4 | NCT01436916 Comparator | Sep 2011 → Sep 2012 | prediabetes syndrome, vitamin D deficiency | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 4 | NCT01277913 Comparator | Jan 2011 → Nov 2013 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT01390480 Comparator | Nov 2010 → Nov 2013 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT01230307 Comparator | Oct 2010 → Dec 2014 | heart failure | University of Michigan | Terminated | No outcome recorded |
| Phase 4 | NCT01237769 Comparator | Oct 2010 → Mar 2012 | metabolic syndrome X | University of Ioannina | Unknown | No outcome recorded |
| Phase 4 | NCT01103934 Comparator | Jun 2010 → Jul 2011 | seasonal allergic rhinitis | University of Chicago | Completed | No outcome recorded |
| Phase 4 | NCT01037140 Comparator | Jan 2010 → Dec 2011 | obesity disorder, vitamin D deficiency | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT02620345 Background | Jan 2010 → Oct 2015 | benign neoplasm of corpus uteri | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01265615 Comparator | Oct 2009 → Apr 2010 | cardio-renal syndrome, chronic transplant rejection | Ural State Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00956839 Comparator | Jul 2009 → Jun 2010 | chronic pancreatitis | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01101698 Comparator | Jun 2009 → Dec 2010 | chronic kidney disease, coronary artery disorder | Medical University of Lodz | Unknown | No outcome recorded |
| Phase 4 | NCT00889629 Background | Nov 2008 → Jan 2010 | chronic kidney disease | Mariana Markell | Completed | No outcome recorded |
| Phase not applicable42 trials | ||||||
| — | NCT07460336 Background | May 2026 → Dec 2027 expected | latent autoimmune diabetes in adults | Second Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| — | NCT07597096 Comparator | May → Jun 2026 overdue | secondary hypoparathyroidism due to impaired parathormon secretion | King Edward Medical University | Not yet recruiting | No outcome recorded |
| — | NCT06861062 Comparator | Apr 2025 → Dec 2030 expected | type 2 diabetes mellitus | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| — | NCT06553729 Comparator | Feb 2025 → Dec 2026 expected | glucose intolerance | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| — | NCT06736093 Comparator | Jan 2025 → May 2026 overdue | — | Institute of Liver and Biliary Sciences, India | Recruiting | No outcome recorded |
| — | NCT06351566 Comparator | Apr → Dec 2024 | type 2 diabetes mellitus | Huazhong University of Science and Technology | Completed | No outcome recorded |
| — | NCT06022237 Background | Sep 2023 → Aug 2024 | cirrhosis of liver, disease of bone structure | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT05879237 Comparator | Jun → Dec 2023 | Helicobacter pylori infectious disease | Minia University | Unknown | No outcome recorded |
| — | NCT05324904 Comparator | Oct 2022 → Oct 2023 | plantar wart | Assiut University | Unknown | No outcome recorded |
| — | NCT06464718 Background | Jun → Dec 2022 | — | Frontier Medical and Dental College, Abbotabad | Completed | No outcome recorded |
| — | NCT05930002 Comparator | Jul 2021 → Sep 2022 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| — | NCT05559619 Comparator | Jul 2021 → Jun 2022 | postmenopausal osteoporosis | Cairo University | Completed | No outcome recorded |
| — | NCT04733625 Comparator | Sep → Dec 2020 | COVID-19 | Kasr El Aini Hospital | Completed | No outcome recorded |
| — | NCT04216459 Comparator | Feb → Nov 2020 | infectious disease with sepsis | Mansoura University | Completed | No outcome recorded |
| — | NCT05266261 Background | Oct 2018 → Aug 2021 | postmenopausal osteoporosis, type 2 diabetes mellitus | Yeouido St. Mary's Hospital | Completed | No outcome recorded |
| — | NCT05880030 Comparator | Oct 2016 → Nov 2022 | iron metabolism disease, myositis disease | Gdansk University of Physical Education and Sport | Completed | No outcome recorded |
| — | NCT03484416 Comparator | Mar 2016 → May 2017 | thyroid cancer | Ewha Womans University Mokdong Hospital | Completed | No outcome recorded |
| — | NCT03504280 Comparator | Apr 2015 → Aug 2017 | vitamin D deficiency | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| — | NCT01759485 Comparator | May 2014 → Sep 2016 | treatment-refractory schizophrenia | Geha Mental Health Center | Completed | No outcome recorded |
| — | NCT01967459 Comparator | Oct 2013 → Dec 2015 | atherosclerosis, leukocyte disorder | Sint Franciscus Gasthuis | Completed | No outcome recorded |
| — | NCT01170494 Comparator | Feb 2013 → Apr 2016 | vitamin D deficiency | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT01385345 Comparator | Aug 2012 → Jan 2014 | vitamin D deficiency | University of Leicester | Terminated | No outcome recorded |
| — | NCT01640496 Comparator | Jul 2012 → Jun 2014 | ulcerative colitis | University of Chicago | Withdrawn | No outcome recorded |
| — | NCT01892748 Comparator | Jul 2012 → Aug 2013 | systemic lupus erythematosus | ROSA MARIA RODRIGUES PEREIRA | Completed | No outcome recorded |
| — | NCT01430793 Comparator | Nov 2011 → Mar 2013 | vitamin D deficiency | Aga Khan University | Completed | No outcome recorded |
| — | NCT01287455 Comparator | Feb 2011 → Feb 2012 | asthma, vitamin D deficiency | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT01214928 Comparator | Jan → May 2011 | chronic renal failure syndrome, vitamin D deficiency | St. Joseph's Healthcare Hamilton | Completed | No outcome recorded |
| — | NCT01240512 Comparator | Dec 2010 → Oct 2013 | hypertensive disorder, vitamin D deficiency | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01337635 Comparator | Nov 2010 → Dec 2012 | atopic eczema, vitamin D deficiency | Medical College of Wisconsin | Terminated | No outcome recorded |
| — | NCT01400009 Comparator | Oct 2010 → Jul 2012 | statin toxicity | McGill University Health Centre/Research Institute of the McGill University Health Centre | Withdrawn | No outcome recorded |
| — | NCT02922803 Comparator | May 2010 → Aug 2016 | myopathy, vitamin D deficiency | Uppsala University | Completed | No outcome recorded |
| — | NCT01425775 Comparator | Apr → Sep 2010 | systemic lupus erythematosus | University of Alexandria | Completed | No outcome recorded |
| — | NCT00893451 Comparator | Sep 2009 → Jun 2011 | chronic kidney disease, vitamin D deficiency | Sahlgrenska University Hospital | Completed | No outcome recorded |
| — | NCT00996866 Comparator | Dec 2008 → Aug 2013 | vitamin D deficiency | Winthrop University Hospital | Terminated | No outcome recorded |
| — | NCT01126671 Comparator | Nov 2008 → Jun 2011 | vitamin D deficiency | Boston Children's Hospital | Completed | No outcome recorded |
| — | NCT00982722 Comparator | Apr 2008 → May 2018 | primary hyperparathyroidism | Karolinska University Hospital | Completed | No outcome recorded |
| — | NCT00459563 Comparator | Mar 2007 → Dec 2011 | hypertensive disorder | Atlanta VA Medical Center | Withdrawn | No outcome recorded |
| — | NCT00450073 Comparator | Nov 2006 → May 2011 | cystic fibrosis | Atlanta VA Medical Center | Completed | No outcome recorded |
| — | NCT00736632 Comparator | May 2006 → Jan 2019 | hypertensive disorder, type 2 diabetes mellitus, vitamin D deficiency | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00285467 Comparator | Jan 2006 → Dec 2009 | renal osteodystrophy | Indiana University | Completed | No outcome recorded |
| — | NCT00427037 Comparator | Dec 2005 → Jul 2006 | chronic kidney disease, vitamin D deficiency | Atlanta VA Medical Center | Completed | No outcome recorded |
| — | NCT00004489 Background | Oct 1998 → Sep 2002 | cystic fibrosis, osteoporosis | University of North Carolina | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-05-31 | Daiichi Sankyo | Daiichi Sankyo Launches Denotas® Chewable Combination Tablets with Calcium/Natural Vitamin D3/Magnesium daiichisankyo.com ↗ |
Evidence & citations 45 cited values
Every value below carries the sentence it was read from. 584 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cholecalciferol | “The investigators hypothesise that supplementation of vitamin D3 (Cholecalciferol), in addition to standard antibiotic and other supportive therapy in the management of...” NCT02185196 ↗322“Genotype 1 or 4 HCV-infected patients with null response to previous PegIFN/RBV treatment and with hypovitaminosis D (< 30 ng/mL) prospectively received cholecalciferol 100000...” PMID 25987791 ↗ May 2015 “Neonates were given vitamin D3 (cholecalciferol) in an oral drops formulation (400 IU/drop), at a dose of 400 IU once a day until the serum bilirubin level was out of...” NCT07098234 ↗ “Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol)...” NCT04677816 ↗ “A new fixed-dose combination (FDC) formulation of raloxifene 60 mg and cholecalciferol 800 IU was developed to improve the medication compliance and overall efficacy of...” PMID 36247744 ↗ Sep 2022 “To investigate the effect of cholecalciferol (vitamin D3) supplementation on peripheral immune cell frequency and N-glycan branching in patients with relapsing-remitting...” PMID 32830462 ↗ Aug 2020 “vitamin D will be obtained from a commercial product in the Egyptian pharmacies called (Devarol S) in the form of injectable ampoules containing 200000 IU of cholecalciferol (2.5 mg/ml)” NCT06570200 ↗ “vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis. for Pharmaceutical and Chemical Industries)” NCT04244474 ↗ “Deficient volunteers (Vit-D serum <30 ng/mL) were assigned (V1) to receive either 100,000 IU/15 days of cholecalciferol (D, n = 19), or a placebo (P, n = 19), over a 3 month period.” PMID 30800121 ↗ Feb 2019 “The patients received oral liquid cholecalciferol supplementation (OsteVit DTM, Key Pharmaceuticals, Macquarie Park, NSW, Australia), supplied in 50 mL bottles (5000 units in 1 mL).” NCT04134065 ↗ “will receive supplementary Vitamin D3(NIVAGEN Vitamin D3 Cholecalciferol 50000 IU) oral once weekly for 3 months as adjuvant therapy in combination with their treatment for ITP.” NCT06073925 ↗ “Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month.” NCT01409694 ↗ “We investigated the effect of the nutrient vitamin D (cholecalciferol), a biochemical precursor of calcitriol, on PSA levels and the rate of rise of PSA in these patients.” PMID 15749627 ↗ 2005 “25-hydroxyvitamin D (cholecalciferol, \[25(OH)D\]) levels \<30 ng/ml will be treated with vitD (20,000 IU/wk) or placebo in a 2:1 randomized controlled trial over 24 weeks” NCT01721915 ↗ “Vitamin D3 (cholecalciferol), the most powerful form of vitamin D, is synthesized in the skin from 7-dehydrocholesterol by action of sunlight (ultraviolet B radiation).” NCT01500005 ↗ “high-dose oral vitamin D3 (VD3; cholecalciferol) combined with photodynamic therapy (PDT) can improve the clearance of squamous precancers (actinic keratoses [AKs]).” PMID 35314199 ↗ Mar 2022 “Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium (by calcium carbonate) and 1,000 IU/day cholecalciferol for 2 weeks” NCT03484416 ↗ “The participants were randomized to 1 of 3 daily treatments: (1) 0.5-1.0 µg calcitriol and 1200 IU (30 µg) cholecalciferol, (2) 1200 IU cholecalciferol, (3) placebo.” PMID 22592096 ↗ May 2012 “National guidelines recommend the administration of 800 IU cholecalciferol daily for an effective treatment, especially during the winter (poor sun exposition).” NCT03141593 ↗ “Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU” NCT02273843 ↗ “patients with recent onset T1D received one dose of allogenic ASC (1 × 106 cells/kg) and cholecalciferol 2,000 UI/day for 6 months (group 1).” PMID 33939911 ↗ Apr 2021 “Subjects received 50,000 IU every 4 to 5 weeks (n = 11) or 100,000 IU every 6 to 8 weeks (n = 32) of oral cholecalciferol for 1 year.” PMID 35045559 ↗ Jan 2022 “The clinical-scientific hypothesis of this study is that replacement of vitamin D (cholecalciferol) will improve the symptoms of RLS.” NCT03063190 ↗ “Patients were randomized 1:1 to receive oral cholecalciferol 100 000 IU (n = 163) or placebo (n = 153) every 2 weeks for 24 months.” PMID 40063041 ↗ Apr 2025 “This intervention consists of oral Vitamin D3 (cholecalciferol) capsules administered every two weeks to improve vitamin D status.” NCT07269223 ↗ “Determination of the effect of cholecalciferol (VitD3) (2200 IU/day) on metabolic parameters in patients with metabolic syndrome.” NCT01237769 ↗ “vitamin D3 (cholecalciferol) supplementation will benefit Veteran subjects diagnosed with early-stage, low-risk prostate cancer” NCT01759771 ↗ “Participants were randomly assigned to either the topical vitamin D group (cholecalciferol 50 mcg) or the topical placebo group” PMID 39372262 ↗ Oct 2024 “A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )” NCT03257215 ↗ “Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4” NCT05002530 ↗ “Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4” NCT05077813 ↗ “Patients with SLE (n = 267) were randomized 2:1 to receive either oral cholecalciferol 2000 IU/day or placebo for 12 months.” PMID 23204220 ↗ Dec 2012 “Cholecalciferol (Vitamin D) is a fat-soluble vitamin that is involved in maintaining the serum calcium-phosphorus gradient.” NCT05166005 ↗ “Each tablet contained 500 milligrams of calcium carbonate and 200 international units (IU) of vitamin D3(cholecalciferol).” NCT04618952 ↗ “The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone supplement (cholecalciferol).” NCT01285401 ↗ “vitamin D3 (an aqueous preparation of cholecalciferol (Devarol® ampoule 200 000 IU/2 ml, Memphis, Egypt) (2.5 mg/ ml)” NCT06327581 ↗ “risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.” NCT01806792 ↗ “once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.” NCT01968850 ↗ “oral cholecalciferol 50,000 U weekly for 8 weeks followed by 10,000 U weekly for 44 weeks or matching placebo” PMID 34656640 ↗ Oct 2021 “Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach blood levels of 60-80 ng/ml of 25(OH)D.” NCT02786875 ↗ “randomized into 3 vitamin D3 (cholecalciferol) treatment arms: 50,000 IU/wk; 5000 IU/d; and 1000 IU/d.” PMID 26707619 ↗ Dec 2015 “It is prepared by using Cholecalciferol 2ml ampoule (200.000 I.U.) within topical oral gel formulation.” NCT04308161 ↗ “Vitamin D3 (cholecalciferol) will be given to the study group Ia orally 50000 IU weekly for 6 weeks.” NCT04529668 ↗ “Cholecalciferol supplementation was fixed at 1000 IU/day (25 mcg/day), both in cases and controls.” NCT03911843 ↗ “cholecalciferol 5,000 IU once/week and cholecalciferol 40,000 IU once/week orally for 24 weeks” NCT04377399 ↗ “AIM: Effect of high dose, oral cholecalciferol supplementation on SARS-CoV-2 viral clearance.” PMID 33184146 ↗ Nov 2020 “The interventional drug, 2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol” NCT06071481 ↗ “The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.” NCT01695460 ↗ “The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,” NCT05324904 ↗ “Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)” NCT02922803 ↗ “oral cholecalciferol supplementation of 250,000 IU during their next CF clinic visit” NCT02613884 ↗ “Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU” NCT02620345 ↗ “Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily” NCT00736632 ↗ “Patients will receive a cholecalciferol supplementation added to a fruit juice.” NCT04775381 ↗ “Cholecalciferol (vitamin D3 \[D3\]) is the main dietary source of vitamin D” NCT03783273 ↗ “Vitamin D3 (cholecalciferol) will be provided to participants of the study.” NCT02996721 ↗ “Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU” NCT02328404 ↗ “One capsule containing (cholecalciferol 400 IU) was taken every day .” NCT04319289 ↗ “Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months” NCT01101698 ↗ “either oral cholecalciferol at 25,000 IU/wk or placebo for 3 months” PMID 29504254 ↗ Mar 2018 “Vitamin D3 or D2 (Cholecalciferol or Ergocalciferol respectively)” NCT03405207 ↗ “100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months.” NCT01102374 ↗ “4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily” NCT03101150 ↗ “<Ibandronate 150mg + cholecalciferol(Vitamin D3) 24,000IU>” NCT01581320 ↗ “Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)” NCT03475719 ↗ “Daily vitamin D (cholecalciferol) tablets and rocaltrol” NCT00497900 ↗ “200,000 IU / 1 mL of Cholecalciferol (1 ml) Oral form” NCT04883203 ↗ “Cholecalciferol (Vitamin D3) and Calcitriol Treatment” NCT00459563 ↗ “150 mg of ibandronate + 24,000 IU of cholecalciferol” NCT05266261 ↗ “the dietary form of Vitamin D (cholecalciferol, D3)” NCT03467789 ↗ “cholecalciferol (vitamin D3) 2000 IU capsules daily” NCT02925195 ↗ “Cholecalciferol 400 IU orally every day for 6 weeks” NCT01337635 ↗ “100000 IU Cholecalciferol Intramuscular every month” NCT04010942 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT01704859 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT01684722 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT01169259 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT04573946 ↗ “Cholecalciferol 50000 IU once monthly orally” NCT00677339 ↗ “either cholecalciferol 50,000 IU or placebo” NCT04489628 ↗ “Cholecalciferol 200000 IU insta ampoule” NCT05104970 ↗ “Vitamin D3 tablets (cholecalciferol)” NCT01741181 ↗ “vitamin D3 1000 IU (Cholecalciferol)” NCT03783338 ↗ “400 IU Vitamin D3 (cholecalciferol)” NCT00412074 ↗ “Dietary Supplement: cholecalciferol” NCT01198548 ↗ “800-6000 IU cholecalciferol per day” NCT01182870 ↗ “Dietary Supplement: Cholecalciferol” NCT00887432 ↗ “Drug: Vitamin D3 (Cholecalciferol)” NCT00956839 ↗ “Cholecalciferol granule 10 mg” NCT03005340 ↗ “Vitamin D3 (Cholecalciferol)” NCT06757244 ↗ “Vitamin D3 (Cholecalciferol)” NCT07269457 ↗ “Vitamin D3 (Cholecalciferol)” NCT04442412 ↗ “Vitamin D3 (Cholecalciferol)” NCT06690723 ↗ “Vitamin D3 (cholecalciferol)” NCT01574027 ↗ “Vitamin D (Cholecalciferol )” NCT07167797 ↗ “Vitamin D3 cholecalciferol” NCT03101319 ↗ “24,000 IU cholecalciferol” NCT04991324 ↗ “cholecalciferol 200,000IU” NCT03233295 ↗ “cholecalciferol” NCT05733117 ↗ |
| Known as | 1,25 dihydroxycholecalciferol | “1,25 dihydroxycholecalciferol (vitamin D3) is the most active hormonal form of vitamin D.” NCT07455656 ↗ |
| Known as | 1,25 Dihydroxyvitamin D3 | “Effects of Vitamin D3 (1,25 Dihydroxyvitamin D3) on Pharmacokinetics and Absorption of Folic Acid and Fexofenadine in Healthy Volunteers” NCT01856348 ↗ |
| Known as | 25-Hydroxyvitamin D | “Cholecalciferol (25-Hydroxyvitamin D)” NCT00798993 ↗ |
| Known as | 25OH vitamin D3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01588795 ↗ |
| Known as | A11CC05 Colecalciferol | “A11CC05 Colecalciferol” NCT01748370 ↗1“A11CC05 Colecalciferol” NCT01721915 ↗ |
| Known as | BABY D3 | “Vitamin D3 as "BABY D3"” NCT01287455 ↗ |
| Known as | cholecalciferol (vitamin D) | “cholecalciferol (vitamin D)” NCT01769625 ↗1“cholecalciferol (Vitamin D)” NCT01425476 ↗ |
| Known as | cholecalciferol (vitamin D3) | “cholecalciferol (vitamin D3)” NCT02172651 ↗ |
| Known as | Colecalciferol | “Vitamin D3 (cholecalciferol, colecalciferol) is one of type of vitamin D which is made by the skin when exposed to sunlight; it is also found in some foods and can be taken as...” NCT01472445 ↗16“Alendronic acid 70mg with Colecalciferol 70mcg” NCT03006003 ↗ “30,000 IU vitamin D (colecalciferol)” NCT04840238 ↗ “Colecalciferol 16.800 IU per week” NCT02122627 ↗ “Vitamin D3 ( Colecalciferol)” NCT01264874 ↗ “Vitamin D3 ( Colecalciferol)” NCT06690723 ↗ “A11CC05 Colecalciferol” NCT01748370 ↗ |
| Known as | Colecalciferol, cholecalciferol, vitamin D3 | “Colecalciferol, cholecalciferol, vitamin D3” NCT02122627 ↗ |
| Known as | d-alpha tocopherol | “Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg...” NCT04134091 ↗ |
| Known as | Dekristol | “Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D” NCT01339676 ↗ |
| Known as | Devarol | “vitamin D3 (an aqueous preparation of cholecalciferol (Devarol® ampoule 200 000 IU/2 ml, Memphis, Egypt)” NCT06327581 ↗ |
| Known as | Devarol S | “The aqueous solution of vitamin D3 is used (Devarol S 200,000IU/2ml ) 0.6 ml (60,000 IU ) will be slowly injected into the base of the largest wart” NCT07196670 ↗ |
| Known as | Devarol- S- 200.000 I.U. | “vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis. for Pharmaceutical and Chemical Industries)” NCT04244474 ↗ |
| Known as | IM vitamin D3 - Inj Arachitol (Solvay, India) | “IM vitamin D3 - Inj Arachitol (Solvay, India)” NCT00956839 ↗ |
| Known as | inactive vitamin D | “Cholecalciferol (inactive vitamin D)” NCT04145492 ↗ |
| Known as | Juvit D3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04768023 ↗ |
| Known as | Maintenance Vitamin D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05846880 ↗ |
| Known as | Naderin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07671508 ↗ |
| Known as | Native Vitamin D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05884372 ↗ |
| Known as | NIVAGEN Vitamin D3 | “will receive supplementary Vitamin D3(NIVAGEN Vitamin D3 Cholecalciferol 50000 IU) oral once weekly for 3 months as adjuvant therapy in combination with their treatment for ITP.” NCT06073925 ↗ |
| Known as | Oral vitamin D3 - Tab Cipcal (Cipla, India) | “Oral vitamin D3 - Tab Cipcal (Cipla, India)” NCT00956839 ↗ |
| Known as | OsteVit DTM | “The patients received oral liquid cholecalciferol supplementation (OsteVit DTM, Key Pharmaceuticals, Macquarie Park, NSW, Australia), supplied in 50 mL bottles (5000 units in 1 mL).” NCT04134065 ↗ |
| Known as | Prostate Health Cocktail | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00669656 ↗ |
| Known as | sodium nucleinate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06209229 ↗ |
| Known as | Sunny D (Vitamin D3) Softgel Capsule | “Sunny D™ (Vitamin D3) Softgel Capsule” NCT05080530 ↗ |
| Known as | TillVal-D | “cholecalciferol (TillVal-D)” NCT00893451 ↗ |
| Known as | TillVal-D, cholecalciferol, vitamin D3 | “TillVal-D, cholecalciferol, vitamin D3” NCT00893451 ↗ |
| Known as | UVEDOSE | “The drug evaluated is vitamin D3 (cholecalciferol), administered in the form of oral solution (2 mL) containing 100,000 IU, manufactured by the laboratory CRINEX and marketed...” NCT03475225 ↗1“vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial)” NCT01480869 ↗ |
| Known as | V drops | “Patients will receive vitamin D drug with generic name: V drops manufactured by Medical Union Pharmaceuticals, Egypt Dosage form: liquid drops Dosage, frequency, and...” NCT02550912 ↗ |
| Known as | VD3 | “high-dose oral vitamin D3 (VD3; cholecalciferol) combined with photodynamic therapy (PDT) can improve the clearance of squamous precancers (actinic keratoses [AKs]).” PMID 35314199 ↗ Mar 20221“4,000 IU of VD3 for at least one year” NCT01759771 ↗ |
| Known as | VDs | “The intervention group received VDs (200,000 IU/1 ml of cholecalciferol); the control group received a placebo treatment (physiological saline (1 ml)).” PMID 36803273 ↗ Feb 2023 |
| Known as | Vigantol | “further substitution of vitamin D in the form of Vigantol 5000I.U. drops administered per os” NCT03588767 ↗ |
| Known as | VigantOL oil | “The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone supplement (cholecalciferol).” NCT01285401 ↗1“Oral Vigantol Oil 5 mls, (100 000 iu of Vitamin D).” NCT02053519 ↗ |
| Known as | VIT D | “We aimed in this study to investigate the safety and efficacy of ASCs + daily cholecalciferol (VIT D) for 6 months in patients with recent-onset T1D.” PMID 33939911 ↗ Apr 2021 |
| Known as | Vitamin D | “Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month.” NCT01409694 ↗30“This research is being done to study the effectiveness of vitamin D (cholecalciferol) to modify hepcidin levels in children with chronic kidney disease (CKD).” NCT01532349 ↗ “Study to Evaluate the Pharmacokinetics of Vitamin D (Cholecalciferol) in Patients Undergoing Obesity Surgery in a Deficit Situation and After Standardization” NCT01637155 ↗ “Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.” NCT01702974 ↗ “Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.” NCT01698476 ↗ “The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.” NCT01695460 ↗ “Does vitamin D (cholecalciferol) supplementation decrease levels of anxiety and depression in patients with post-COVID-19 condition?” NCT06419712 ↗ “Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4” NCT05002530 ↗ “Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4” NCT05077813 ↗ “Cholecalciferol (Vitamin D) is a fat-soluble vitamin that is involved in maintaining the serum calcium-phosphorus gradient.” NCT05166005 ↗ “7000 IU, or 30000 IU Vitamin D (Cholecalciferol) to a 1000 IU Dosage Applied Daily in Vitamin D Deficient Patients” NCT02069990 ↗ “Low dose Vitamin D is 800 IU cholecalciferol per day and high dose vitamin D is 2000 IU cholecalciferol per day.” NCT00133640 ↗ “Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach blood levels of 60-80 ng/ml of 25(OH)D.” NCT02786875 ↗ “Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate” NCT00682214 ↗ “Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months” NCT01101698 ↗ “Patients receiving 3 doses of vitamin D (cholecalciferol)” NCT02002000 ↗ “Daily vitamin D (cholecalciferol) tablets and rocaltrol” NCT00497900 ↗ “Oral cholecalciferol (vitamin D)60,000 IU weekly” NCT00507000 ↗ “vitamin D (cholecalciferol) supplementation” NCT06585995 ↗ “30,000 IU vitamin D (colecalciferol)” NCT04840238 ↗ “Vitamin D - Cholecalciferol 400 IU” NCT01419262 ↗ “Vitamin D (Cholecalciferol )” NCT07167797 ↗ “Vitamin D (Cholecalciferol )” NCT06596122 ↗ “Vitamin D (Cholecalciferol )” NCT01400009 ↗ “Vitamin D (Cholecalciferol )” NCT07448974 ↗ “Vitamin D (Cholecalciferol )” NCT07229456 ↗ “Vitamin D (cholecalciferol)” NCT02197286 ↗ “Drug: Vitamin D” NCT05733117 ↗ “vitamin D” NCT01037140 ↗ “vitamin D” NCT04733625 ↗ “vitamin D” NCT04535791 ↗ |
| Known as | vitamin D3 | “A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK -0217A/Alendronate Sodium-70...” NCT00692913 ↗313“Fifty-three subjects were randomly assigned in an open-label, randomized controlled trial to receive either an energy-restricted diet (-500 kcal/d) supplemented with 600 mg...” PMID 23297844 ↗ Jan 2013 “Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol)...” NCT04677816 ↗ “Combination therapy with raloxifene, a selective estrogen receptor modulator, and cholecalciferol (vitamin D3 ) has been proposed to improve the overall efficacy and increase...” PMID 34984851 ↗ Jan 2022 “vitamin D group received treatment dose of 50,000 IU of vitamin D3 per week for 2 consecutive months and placebo group received placebo tablets similar in size, shape and color...” NCT03310307 ↗ “The main objective of this study is to evaluate the efficacy and tolerance of 2 years of treatment with cholecalciferol (vitamin D3) in patients with a clinically isolated...” NCT01817166 ↗ “This is a one-year multi-centre, double blind, placebo controlled, randomized trial investigating oral vitamin D3 (Colecalciferol) as an add-on treatment to interferon-beta-1b...” NCT01432704 ↗ “The objective was to ascertain the efficacy of weekly very-high-dose cholecalciferol (vitamin D(3)) in correcting vitamin D insufficiency and deficiency in patients with stage...” PMID 22237061 ↗ Jan 2012 “The drug evaluated is vitamin D3 (cholecalciferol), administered in the form of oral solution (2 mL) containing 100,000 IU, manufactured by the laboratory CRINEX and marketed...” NCT03475225 ↗ “Vitamin D3 (cholecalciferol, colecalciferol) is one of type of vitamin D which is made by the skin when exposed to sunlight; it is also found in some foods and can be taken as...” NCT01472445 ↗ “To investigate the effect of cholecalciferol (vitamin D3) supplementation on peripheral immune cell frequency and N-glycan branching in patients with relapsing-remitting...” PMID 32830462 ↗ Aug 2020 “In addition, oral vitamin D3 (80,000 IU per week) and placebo will be added to the treatment schedule of the 'Study' patients and 'Control' patients, respectively, for...” NCT04011930 ↗ “Participants in this group will receive a combination therapy of Vitamin D3 plus a daily oral probiotic capsule containing a standardized blend of Lactobacillus and...” NCT07115342 ↗ “Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU,...” NCT02421887 ↗ “Cholecalciferol (vitamin D3) is still considered the most promising vitamin D dosage form due to its long half-life, large safety window, and convenience (over-the-counter medication).” NCT05270343 ↗ “Subjects will be randomized to receive either vitamin D3 (cholecalciferol) or a matching placebo at a dose of 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.” NCT01388855 ↗ “vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis. for Pharmaceutical and Chemical Industries)” NCT04244474 ↗ “Cholecalciferol or vitamin D3; the native inactivated 25-hydroxy vitamin D [25(OH)D], has been proposed to have a good impact on vascular calcification and vitamin D deficiency.” PMID 33594986 ↗ Sep 2020 “will receive supplementary Vitamin D3(NIVAGEN Vitamin D3 Cholecalciferol 50000 IU) oral once weekly for 3 months as adjuvant therapy in combination with their treatment for ITP.” NCT06073925 ↗ “Group B All Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe.” NCT04428359 ↗ “Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.” NCT04177758 ↗ “a single oral high dose of cholecalciferol (vitamin D3) administered within 72 hours after the diagnosis of COVID-19 improves, compared to standard-dose cholecalciferol” PMID 35639792 ↗ May 2022 “Participants were randomly assigned to receive either a capsule containing 4,000 IU of vitamin D3 (cholecalciferol, n=52) or placebo (n=52), once a day during 6 months.” NCT01019642 ↗ “Vitamin D3 (cholecalciferol), the most powerful form of vitamin D, is synthesized in the skin from 7-dehydrocholesterol by action of sunlight (ultraviolet B radiation).” NCT01500005 ↗ “High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day” NCT01385345 ↗ “Vitamin D(3) supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: Results of an open label randomized clinical trial.” PMID 27302208 ↗ Jun 2016 “Intramuscular injection of 300,000 IU of vitamin D3 in patients with low serum levels of 25(OH)D undergoing craniotomy, could rise safely the serum 25(OH)D level.” PMID 33487259 ↗ Jan 2021 “Sub-lingual Omega 3 FA and Vitamin D3 supplements for 6 months, twice daily ,1/2 tea spoon with instructions to keep it under the tongue for 45 sec.” NCT02294149 ↗ “Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.” NCT03369379 ↗ “Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a tablet containing 1600IU of Cholecalciferol (Vitamin D3)” NCT00610688 ↗ “Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.” NCT02698293 ↗ “patients with vitamin D deficiency (≤ 20 ng/ml) were randomized to receive vitamin D3 (cholecalciferol, 540,000 IU) (n = 134) or placebo.” PMID 31518978 ↗ Sep 2019 “Effects of Vitamin D3 (1,25 Dihydroxyvitamin D3) on Pharmacokinetics and Absorption of Folic Acid and Fexofenadine in Healthy Volunteers” NCT01856348 ↗ “Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days” NCT03472833 ↗ “Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3).” NCT05149339 ↗ “This study will assess the safety of a one-time high dose of cholecalciferol or vitamin D3 along with the efficacy and feasibility.” NCT02613884 ↗ “Eligible patients will then be randomly assigned to receive either vitamin D3 (2400 IU/day) or 25(OH)D3 (20 mcg/day) for 16 weeks.” NCT02091219 ↗ “Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU” NCT00844792 ↗ “Each tablet contained 500 milligrams of calcium carbonate and 200 international units (IU) of vitamin D3(cholecalciferol).” NCT04618952 ↗ “Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)” NCT01024777 ↗ “CXCL10 gene expression is downregulated in monocytes by metabolically active vitamin D3 (1,25dihydroxy vitamin D).” PMID 24670704 ↗ Apr 2014 “supplementation with 1250 mg calcium carbonate and 400 IU of vitamin D3 in risperidone-induced hyperprolactinemia.” PMID 29112461 ↗ Nov 2017 “once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.” NCT01968850 ↗ “Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) 5 drops/day for 3 months (Reuterin D3 drops)” NCT02734446 ↗ “Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months” NCT05417880 ↗ “will be randomized to receive either vitamin D3 (cholecalciferol) 3200U orally (tablets) daily or placebo” NCT00893451 ↗ “the dose of oral vitamin D3 supplement exceeds current recommendations to achieve adequate desired level” NCT00327847 ↗ “Vitamin D3 (cholecalciferol) will be given to the study group Ia orally 50000 IU weekly for 6 weeks.” NCT04529668 ↗ “Subjects with HIV (8-24 years) were randomized to vitamin D3 supplementation of 4000 or 7000 IU/day” PMID 23059649 ↗ Mar 2013 “Impact of Vitamin D3 Supplementation in Non-Sjogren Dry Eye Patients With Low Serum Vitamin D Level” NCT05425914 ↗ “oral vitamin D3 (cholecalciferol 1000-2000 IU once daily) for 7 days prior to total thyroidectomy” NCT07597096 ↗ “vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial)” NCT01480869 ↗ “Treatment (8 weeks): Daily vitamin D3 pills (2000 IU, free); patients keep a medication diary.” NCT07598032 ↗ “oral 2.000 IU vitamin D3 (cholecalciferol) daily, in addition to routine ANC supplementations” NCT07510568 ↗ “24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month” NCT01017354 ↗ “The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.” NCT01695460 ↗ “Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,” NCT02571660 ↗ “The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,” NCT05324904 ↗ “Participants will receive oral vitamin D3, cholecalciferol 20,000 IU or 30,000 IU weekly.” NCT00859651 ↗ “topical application of vitamin D3 (an aqueous preparation of cholecalciferol (2.5 mg/ ml)” NCT06327581 ↗ “Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.” NCT02400151 ↗ “The proposed study investigates safety and efficacy of a new topical vitamin D3 compound.” NCT02676674 ↗ “all subjects will receive Calcium Carbonate and Vitamin D3 Tablets as basic medication.” NCT05305183 ↗ “supplemental high-dose oral vitamin D3 (four doses of 2·5 mg at weeks 0, 2, 4, and 6)” PMID 25863562 ↗ Apr 2015 “50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.” NCT01295034 ↗ “vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)” NCT01074216 ↗ “using vitamin D3 (cholecalciferol), which has a better effect on the human body” NCT05216419 ↗ “10,000 international units of cholecalciferol (vitamin D3) by mouth weekly” NCT01022398 ↗ “oral intake of vitamin D3 (cholecalciferol) with the effect of a placebo” NCT01409694 ↗ “Participants receive Vitamin D3 (dose: 800 IU/day, orally, for 4 weeks)” NCT07045883 ↗ “Take 400 units of vitamin D3, twice daily, for a duration of 3 months.” NCT06539260 ↗ “elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements” NCT02143505 ↗ “Subjects are randomized to take 200 IU vitamin D3 daily in this arm.” NCT01126671 ↗ “vitamin D3 (cholecalciferol) 40 000 IU/week or placebo for 6 months” NCT00809744 ↗ “Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months.” NCT00279461 ↗ “Study Drug: Oral cholecalciferol (Vitamin D3 capsule 200,000 IU).” NCT05080530 ↗ “receive vitamin D3 (cholecalciferol) either at high or low dose” PMID 25376735 ↗ Nov 2014 “100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months.” NCT01102374 ↗ “Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E” NCT00744549 ↗ “Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose” NCT01075022 ↗ “<Ibandronate 150mg + cholecalciferol(Vitamin D3) 24,000IU>” NCT01581320 ↗ “Vitamin D3, Cholecalciferol, 5000IU po qday for 12 weeks” NCT01884844 ↗ “Vitamin D3 Supplementation in Polymorphic Light Eruption” NCT01595893 ↗ “Calcium 500 mg and vitamin D3 1000 IU chewable tablets” NCT02338713 ↗ “receive 1600 or 800 IU/day of vitamin D3 for 2 years” PMID 33158822 ↗ Nov 2020 “cholecalciferol (vitamin D3) 2000 IU capsules daily” NCT02925195 ↗ “interventional high dose Vitamin D3 supplementation” NCT01535508 ↗ “daily oral EGCG (300 mg) and vitamin D3 (2000 IU)” NCT07647198 ↗ “received oral vitamin D3 (vitamin D-3 2000 IU)” NCT06565728 ↗ “Dietary Supplement: Vitamin D3 supplementation” NCT02802722 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT01684722 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT01169259 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT04573946 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT02178410 ↗ “Vitamin D3 (cholecalciferol), 2000 IU per day.” NCT01704859 ↗ “Vitamin D3 supplementation (2 00,000 IU/Week)” NCT06139133 ↗ “oral cholecalciferol 1000000 UI (vitamin D3)” NCT01656070 ↗ “Cholecalciferol (Vitamin D3) 100 000 IU/2 mL” NCT04115982 ↗ “selenised yeast rich in vitamin D3 (400IU)” NCT06464718 ↗ “100.000 I.U. Cholecalciferol (Vitamin D3)” NCT01845142 ↗ “Group 3: Vitamin D3 50000 units tablet” NCT06618365 ↗ “vitamin D3 1000 IU (Cholecalciferol)” NCT03783338 ↗ “Vitamin D3 - Cholecalciferol 2000 IU” NCT01419262 ↗ “Colecalciferol (Vitamin D3) 50000 UI” NCT07012161 ↗ “Vitamin D3 tablets (cholecalciferol)” NCT01741181 ↗ “70µg Vitamin D3, daily, 12 weeks” NCT01462058 ↗ “Dietary Supplement: Vitamin D3” NCT05008003 ↗ “Vitamin D3 (cholecalciferol)” NCT01636570 ↗ “Cholecalciferol (Vitamin D3)” NCT05430087 ↗ “cholecalciferol (Vitamin D3)” NCT00491920 ↗ “Cholecalciferol (vitaminD3)” NCT04411901 ↗ “Drug: High-dose vitamin D 3” NCT02273843 ↗ “Cholecalciferol (vitaminD3)” NCT07068282 ↗ “Cholecalciferol(Vitamin D3)” NCT01138475 ↗ “Vitamin D3 2000-4000 IU/day” NCT05930002 ↗ “Vitamin D3 cholecalciferol” NCT01955577 ↗ “Single dose vitamin D3” NCT03783273 ↗ “6000 IU of vitamin D3” NCT02656121 ↗ “Vitamin D3 5000IU/day” NCT04591600 ↗ “Vitamin D3” NCT01240512 ↗ “Vitamin D3” NCT01892748 ↗ |
| Known as | Vitamin D3 B.O.N. Injection | “Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)” NCT02443246 ↗1“Vitamin D3 B.O.N. Injection” NCT03233295 ↗ |
| Known as | VitD3 | “AIMS: This open-labeled, randomized clinical trial, compared the impact of daily (2000 IU/D) verses monthly (40,000 IU/month) vitD3 supplementation over six months on markers...” PMID 27302208 ↗ Jun 20165“Determination of the effect of cholecalciferol (VitD3) (2200 IU/day) on metabolic parameters in patients with metabolic syndrome.” NCT01237769 ↗ “subjects infected with HIV ages 8.3 to 24.9 years were randomized to vitD3 supplementation of 4000 IU/day or 7000 IU/day” PMID 26625449 ↗ Mar 2014 “Group B intralesional Vit D3” NCT05739786 ↗ “Cholecalciferol (Vit D3)” NCT07673497 ↗ “Cholecalciferol (Vit D3)” NCT01092338 ↗ |
| Action | Restore | “Restoring vitamin D availability to normal levels in patients with RA may induce improvement of disease manifestations” NCT00279461 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “combination herbal supplement” NCT00669656 ↗ |
| Route | Oral | “oral calcium carbonate and cholecalciferol daily” NCT00004488 ↗ |
| Target | PRODH | “vitD significantly up-regulates PRODH gene expression” NCT02197286 ↗ |